336 related articles for article (PubMed ID: 11322267)
1. Zidovudine plus didanosine in primary HIV-1 infection.
Perrin L; Yerly S; Charvier A; Figueras G; Schockmel GA; Hirschel B
Antivir Ther; 1997 Jan; 2(1):5-11. PubMed ID: 11322267
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of a combination of three reverse transcriptase inhibitors in HIV-1 infection.
Lafeuillade A; Poggi C; Djediouane A; Chollet L; Profizi N; Sayada C
Antivir Ther; 1997 Dec; 2(4):219-27. PubMed ID: 11327441
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
[TBL] [Abstract][Full Text] [Related]
4. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
[TBL] [Abstract][Full Text] [Related]
5. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
7. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
[TBL] [Abstract][Full Text] [Related]
8. Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters.
Capiluppi B; Ciuffreda D; Quinzan GP; Sciandra M; Marroni M; Morandini B; Costigliola P; Guerra L; Di Pietro M; Fibbia GF; Visonà R; Cusini M; Bressi C; Tambussi G; Lazzarin A
J Biol Regul Homeost Agents; 2000; 14(1):58-62. PubMed ID: 10763896
[TBL] [Abstract][Full Text] [Related]
9. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Rubio A; Gómez-Cano M; Puig T; Leal M; Pérez-Olmeda M; Ruiz L; Clotet B; Rey C; Zamora L; Xaus N; Soriano V
Antivir Ther; 1999; 4(1):45-9. PubMed ID: 10682128
[TBL] [Abstract][Full Text] [Related]
10. The role of didanosine in the management of HIV-1 infection.
Gazzard BG; Moyle GJ
Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
[TBL] [Abstract][Full Text] [Related]
11. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
[No Abstract] [Full Text] [Related]
13. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
14. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
[TBL] [Abstract][Full Text] [Related]
15. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Duvivier C; Myrto A; Marcelin AG; Ghosn J; Ait-Mohand H; Schneider L; Agher R; Bricaire F; Costagliola D; Calvez V; Peytavin G; Katlama C
Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
[TBL] [Abstract][Full Text] [Related]
17. Successful simplification of HAART in patients with acute primary HIV infection.
Sinicco A; Bonora S; Arnaudo I; Zeme DA; Audagnotto S; Raiteri R; Di Perri G
J Biol Regul Homeost Agents; 2002; 16(1):69-72. PubMed ID: 12003178
[TBL] [Abstract][Full Text] [Related]
18. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Whitfield RM; Bechtel LM; Starich GH
Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
[TBL] [Abstract][Full Text] [Related]
19. Acute HIV infection.
Perrin L; Yerly S
J Biol Regul Homeost Agents; 1995; 9(3):95-9. PubMed ID: 8782015
[TBL] [Abstract][Full Text] [Related]
20. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
